MedTrace Logo

Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer

NCT02715882 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-02-09

No results posted yet for this study

Summary

Randomized Single-blind Placebo-controlled Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer, With Different Doses and Regimens

Conditions

Interventions

DRUG

CBLB502

DRUG

Placebo

Sponsors & Collaborators

  • Cleveland BioLabs, Inc.

    collaborator INDUSTRY

  • BioLab 612 LLC

    lead INDUSTRY

Principal Investigators

  • Sergei I. Achkasov, MD PhD · Federal State Budgetary Institution "State Scientific Center of Coloproctology named after A.N. Ryzhikh" Ministry of Health of the Russian Federation

  • Nikolay V. Kislov, MD PhD · Federal State Institution of Health of the Yaroslav Region "Regional Clinical Oncology Hospital"

  • Sergei V. Odintcov, MD PhD · Federal State Budgetary Institution "Central Clinical Hospital with polyclinic" Department of Presidential Affairs of the Russian Federation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2017-02-28
Completion
2017-12-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02715882 on ClinicalTrials.gov